Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne Luoma(Harvard University), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Shengbao Suo(Guangzhou Experimental Station), Genevieve M. Boland(Harvard University), Hannah L. Williams(Cancer Research UK), Tatyana Sharova(Harvard University), Guo‐Cheng Yuan(Dana-Farber Cancer Institute), Michael Dougan(Harvard University), Peter J. Bowling(Harvard University), Jonathan A. Nowak(Brigham and Women's Hospital), Michael P. Manos(Harvard University), Keri M. Sullivan(Massachusetts General Hospital), Osama E. Rahma(Dana-Farber/Harvard Cancer Center), Stephanie K. Dougan(Dana-Farber Cancer Institute), F. Stephen Hodi(Harvard University), Ryan J. Sullivan(Dana-Farber Cancer Institute)
Cited by 478
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k